APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Malignant Mesothelioma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Malignant Mesothelioma Drugs Market Outlook and Growth Opportunities 2026

20 December 2025204 pages

Choose your research edition.

Industry ResearchMalignant Mesothelioma Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Mesothelioma Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Malignant Mesothelioma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Mesothelioma Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Mesothelioma Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Malignant Mesothelioma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Malignant Mesothelioma Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Malignant Mesothelioma Drugs market include Teva Pharmaceuticals, Sun Pharmaceuticals, Sanofi, Novartis, Merck, Mylan, Roche, Eli Lilly and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Malignant Mesothelioma Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Malignant Mesothelioma Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Malignant Mesothelioma Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Malignant Mesothelioma Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Malignant Mesothelioma Drugs Segment by Company

Teva Pharmaceuticals

Sun Pharmaceuticals

Sanofi

Novartis

Merck

Mylan

Roche

Eli Lilly

Pfizer

Fresenius Kabi

AstraZeneca

Polaris Pharmaceuticals

Ono Pharmaceutical

Nichi-Iko Pharmaceutical

MolMed

Kyowa Hakko Kirin

Corden Pharma

Concordia International

Bristol-Myers Squibb

Boehringer Ingelheim GmbH

Malignant Mesothelioma Drugs Segment by Type

Vinorelbine

Cisplatin

Pemetrexed

Carboplatin

Gemcitabine

Others

Malignant Mesothelioma Drugs Segment by Application

Retail Pharmacies

Hospital Pharmacies

Oncology Centers

Others

Malignant Mesothelioma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Malignant Mesothelioma Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Malignant Mesothelioma Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Malignant Mesothelioma Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Malignant Mesothelioma Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Malignant Mesothelioma Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Malignant Mesothelioma Drugs industry.

Chapter 3: Detailed analysis of Malignant Mesothelioma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Malignant Mesothelioma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Malignant Mesothelioma Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Malignant Mesothelioma Drugs Industry Trends Table 2. Malignant Mesothelioma Drugs Industry Drivers Table 3. Malignant Mesothelioma Drugs Industry Opportunities and Challenges Table 4. Malignant Mesothelioma Drugs Industry Restraints Table 5. Global Malignant Mesothelioma Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Malignant Mesothelioma Drugs Revenue Share by Company (2021-2026) Table 7. Global Malignant Mesothelioma Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Malignant Mesothelioma Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Malignant Mesothelioma Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Malignant Mesothelioma Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Malignant Mesothelioma Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Malignant Mesothelioma Drugs Company, Product Type & Application Table 13. Global Malignant Mesothelioma Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Malignant Mesothelioma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vinorelbine Table 18. Significant Companies of Cisplatin Table 19. Significant Companies of Pemetrexed Table 20. Significant Companies of Carboplatin Table 21. Significant Companies of Gemcitabine Table 22. Significant Companies of Others Table 23. Global Malignant Mesothelioma Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Malignant Mesothelioma Drugs Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Malignant Mesothelioma Drugs Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Malignant Mesothelioma Drugs Sales Volume Share by Type (2021-2026) Table 27. Global Malignant Mesothelioma Drugs Sales Volume Share by Type (2027-2032) Table 28. Global Malignant Mesothelioma Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Malignant Mesothelioma Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Malignant Mesothelioma Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Malignant Mesothelioma Drugs Sales Value Share by Type (2021-2026) Table 32. Global Malignant Mesothelioma Drugs Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Retail Pharmacies Table 34. Significant Companies of Hospital Pharmacies Table 35. Significant Companies of Oncology Centers Table 36. Significant Companies of Others Table 37. Global Malignant Mesothelioma Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Malignant Mesothelioma Drugs Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Malignant Mesothelioma Drugs Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Malignant Mesothelioma Drugs Sales Volume Share by Application (2021-2026) Table 41. Global Malignant Mesothelioma Drugs Sales Volume Share by Application (2027-2032) Table 42. Global Malignant Mesothelioma Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Malignant Mesothelioma Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Malignant Mesothelioma Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Malignant Mesothelioma Drugs Sales Value Share by Application (2021-2026) Table 46. Global Malignant Mesothelioma Drugs Sales Value Share by Application (2027-2032) Table 47. Global Malignant Mesothelioma Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Malignant Mesothelioma Drugs Sales by Region (2021-2026) & (K Units) Table 49. Global Malignant Mesothelioma Drugs Sales Market Share by Region (2021-2026) Table 50. Global Malignant Mesothelioma Drugs Sales by Region (2027-2032) & (K Units) Table 51. Global Malignant Mesothelioma Drugs Sales Market Share by Region (2027-2032) Table 52. Global Malignant Mesothelioma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Malignant Mesothelioma Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Malignant Mesothelioma Drugs Sales Value Share by Region (2021-2026) Table 55. Global Malignant Mesothelioma Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Malignant Mesothelioma Drugs Sales Value Share by Region (2027-2032) Table 57. Global Malignant Mesothelioma Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Malignant Mesothelioma Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Malignant Mesothelioma Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Malignant Mesothelioma Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 62. Global Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2026) Table 63. Global Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 64. Global Malignant Mesothelioma Drugs Sales Market Share by Country (2027-2032) Table 65. Global Malignant Mesothelioma Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Malignant Mesothelioma Drugs Sales Value Market Share by Country (2021-2026) Table 67. Global Malignant Mesothelioma Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Malignant Mesothelioma Drugs Sales Value Market Share by Country (2027-2032) Table 69. Teva Pharmaceuticals Company Information Table 70. Teva Pharmaceuticals Business Overview Table 71. Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 73. Teva Pharmaceuticals Recent Development Table 74. Sun Pharmaceuticals Company Information Table 75. Sun Pharmaceuticals Business Overview Table 76. Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 78. Sun Pharmaceuticals Recent Development Table 79. Sanofi Company Information Table 80. Sanofi Business Overview Table 81. Sanofi Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Sanofi Malignant Mesothelioma Drugs Product Portfolio Table 83. Sanofi Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Novartis Malignant Mesothelioma Drugs Product Portfolio Table 88. Novartis Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Merck Malignant Mesothelioma Drugs Product Portfolio Table 93. Merck Recent Development Table 94. Mylan Company Information Table 95. Mylan Business Overview Table 96. Mylan Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Mylan Malignant Mesothelioma Drugs Product Portfolio Table 98. Mylan Recent Development Table 99. Roche Company Information Table 100. Roche Business Overview Table 101. Roche Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Roche Malignant Mesothelioma Drugs Product Portfolio Table 103. Roche Recent Development Table 104. Eli Lilly Company Information Table 105. Eli Lilly Business Overview Table 106. Eli Lilly Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Eli Lilly Malignant Mesothelioma Drugs Product Portfolio Table 108. Eli Lilly Recent Development Table 109. Pfizer Company Information Table 110. Pfizer Business Overview Table 111. Pfizer Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Pfizer Malignant Mesothelioma Drugs Product Portfolio Table 113. Pfizer Recent Development Table 114. Fresenius Kabi Company Information Table 115. Fresenius Kabi Business Overview Table 116. Fresenius Kabi Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio Table 118. Fresenius Kabi Recent Development Table 119. AstraZeneca Company Information Table 120. AstraZeneca Business Overview Table 121. AstraZeneca Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. AstraZeneca Malignant Mesothelioma Drugs Product Portfolio Table 123. AstraZeneca Recent Development Table 124. Polaris Pharmaceuticals Company Information Table 125. Polaris Pharmaceuticals Business Overview Table 126. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 128. Polaris Pharmaceuticals Recent Development Table 129. Ono Pharmaceutical Company Information Table 130. Ono Pharmaceutical Business Overview Table 131. Ono Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 133. Ono Pharmaceutical Recent Development Table 134. Nichi-Iko Pharmaceutical Company Information Table 135. Nichi-Iko Pharmaceutical Business Overview Table 136. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 138. Nichi-Iko Pharmaceutical Recent Development Table 139. MolMed Company Information Table 140. MolMed Business Overview Table 141. MolMed Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. MolMed Malignant Mesothelioma Drugs Product Portfolio Table 143. MolMed Recent Development Table 144. Kyowa Hakko Kirin Company Information Table 145. Kyowa Hakko Kirin Business Overview Table 146. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio Table 148. Kyowa Hakko Kirin Recent Development Table 149. Corden Pharma Company Information Table 150. Corden Pharma Business Overview Table 151. Corden Pharma Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Corden Pharma Malignant Mesothelioma Drugs Product Portfolio Table 153. Corden Pharma Recent Development Table 154. Concordia International Company Information Table 155. Concordia International Business Overview Table 156. Concordia International Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Concordia International Malignant Mesothelioma Drugs Product Portfolio Table 158. Concordia International Recent Development Table 159. Bristol-Myers Squibb Company Information Table 160. Bristol-Myers Squibb Business Overview Table 161. Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio Table 163. Bristol-Myers Squibb Recent Development Table 164. Boehringer Ingelheim GmbH Company Information Table 165. Boehringer Ingelheim GmbH Business Overview Table 166. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio Table 168. Boehringer Ingelheim GmbH Recent Development Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. Malignant Mesothelioma Drugs Distributors List Table 172. Malignant Mesothelioma Drugs Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Malignant Mesothelioma Drugs Product Image Figure 2. Global Malignant Mesothelioma Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malignant Mesothelioma Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Malignant Mesothelioma Drugs Sales (2021-2032) & (K Units) Figure 5. Global Malignant Mesothelioma Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Malignant Mesothelioma Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vinorelbine Image Figure 10. Cisplatin Image Figure 11. Pemetrexed Image Figure 12. Carboplatin Image Figure 13. Gemcitabine Image Figure 14. Others Image Figure 15. Global Malignant Mesothelioma Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Malignant Mesothelioma Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Malignant Mesothelioma Drugs Sales Volume Share by Type (2021-2032) Figure 18. Global Malignant Mesothelioma Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Malignant Mesothelioma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Malignant Mesothelioma Drugs Sales Value Share by Type (2021-2032) Figure 21. Retail Pharmacies Image Figure 22. Hospital Pharmacies Image Figure 23. Oncology Centers Image Figure 24. Others Image Figure 25. Global Malignant Mesothelioma Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Malignant Mesothelioma Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Malignant Mesothelioma Drugs Sales Volume Share by Application (2021-2032) Figure 28. Global Malignant Mesothelioma Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Malignant Mesothelioma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Malignant Mesothelioma Drugs Sales Value Share by Application (2021-2032) Figure 31. Global Malignant Mesothelioma Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Malignant Mesothelioma Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Malignant Mesothelioma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Malignant Mesothelioma Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Malignant Mesothelioma Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. North America Malignant Mesothelioma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Malignant Mesothelioma Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Malignant Mesothelioma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Malignant Mesothelioma Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Malignant Mesothelioma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Malignant Mesothelioma Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. South America Malignant Mesothelioma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Malignant Mesothelioma Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Malignant Mesothelioma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Malignant Mesothelioma Drugs Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Malignant Mesothelioma Drugs Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Vinorelbine
  • Cisplatin
  • Pemetrexed
  • Carboplatin
  • Gemcitabine
  • Others
Applications
  • Retail Pharmacies
  • Hospital Pharmacies
  • Oncology Centers
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Sanofi
  • Novartis
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Fresenius Kabi
  • AstraZeneca
  • Polaris Pharmaceuticals
  • Ono Pharmaceutical
  • Nichi-Iko Pharmaceutical
  • MolMed
  • Kyowa Hakko Kirin
  • Corden Pharma
  • Concordia International
  • Bristol-Myers Squibb
  • Boehringer Ingelheim GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Malignant Mesothelioma Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Malignant Mesothelioma Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Malignant Mesothelioma Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Malignant Mesothelioma Drugs Market Dynamics
  1. 2.1 Malignant Mesothelioma Drugs Industry Trends
  2. 2.2 Malignant Mesothelioma Drugs Industry Drivers
  3. 2.3 Malignant Mesothelioma Drugs Industry Opportunities and Challenges
  4. 2.4 Malignant Mesothelioma Drugs Industry Restraints
3 Malignant Mesothelioma Drugs Market by Company
  1. 3.1 Global Malignant Mesothelioma Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Malignant Mesothelioma Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Malignant Mesothelioma Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Malignant Mesothelioma Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Malignant Mesothelioma Drugs Company Ranking (2024-2026)
  6. 3.6 Global Malignant Mesothelioma Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Malignant Mesothelioma Drugs Company Product Type and Application
  8. 3.8 Global Malignant Mesothelioma Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Malignant Mesothelioma Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Malignant Mesothelioma Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Malignant Mesothelioma Drugs Market by Type
  1. 4.1 Malignant Mesothelioma Drugs Type Introduction
  2. 4.1.1 Vinorelbine
  3. 4.1.2 Cisplatin
  4. 4.1.3 Pemetrexed
  5. 4.1.4 Carboplatin
  6. 4.1.5 Gemcitabine
  7. 4.1.6 Others
  8. 4.2 Global Malignant Mesothelioma Drugs Sales Volume by Type
  9. 4.2.1 Global Malignant Mesothelioma Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Malignant Mesothelioma Drugs Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Malignant Mesothelioma Drugs Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Malignant Mesothelioma Drugs Sales Value by Type
  13. 4.3.1 Global Malignant Mesothelioma Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Malignant Mesothelioma Drugs Sales Value by Type (2021-2032)
  15. 4.3.3 Global Malignant Mesothelioma Drugs Sales Value Share by Type (2021-2032)
5 Malignant Mesothelioma Drugs Market by Application
  1. 5.1 Malignant Mesothelioma Drugs Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Oncology Centers
  5. 5.1.4 Others
  6. 5.2 Global Malignant Mesothelioma Drugs Sales Volume by Application
  7. 5.2.1 Global Malignant Mesothelioma Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Malignant Mesothelioma Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Malignant Mesothelioma Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Malignant Mesothelioma Drugs Sales Value by Application
  11. 5.3.1 Global Malignant Mesothelioma Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Malignant Mesothelioma Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Malignant Mesothelioma Drugs Sales Value Share by Application (2021-2032)
6 Malignant Mesothelioma Drugs Regional Sales and Value Analysis
  1. 6.1 Global Malignant Mesothelioma Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Malignant Mesothelioma Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Malignant Mesothelioma Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Malignant Mesothelioma Drugs Sales by Region (2027-2032)
  5. 6.3 Global Malignant Mesothelioma Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Malignant Mesothelioma Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Malignant Mesothelioma Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Malignant Mesothelioma Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Malignant Mesothelioma Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Malignant Mesothelioma Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Malignant Mesothelioma Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Malignant Mesothelioma Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Malignant Mesothelioma Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Malignant Mesothelioma Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Malignant Mesothelioma Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Malignant Mesothelioma Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Malignant Mesothelioma Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Malignant Mesothelioma Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Malignant Mesothelioma Drugs Sales Value Share by Country, 2025 VS 2032
7 Malignant Mesothelioma Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Malignant Mesothelioma Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Malignant Mesothelioma Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Malignant Mesothelioma Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Malignant Mesothelioma Drugs Sales by Country (2027-2032)
  6. 7.4 Global Malignant Mesothelioma Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Malignant Mesothelioma Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Malignant Mesothelioma Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Malignant Mesothelioma Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Malignant Mesothelioma Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Malignant Mesothelioma Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Sun Pharmaceuticals
  8. 8.2.1 Sun Pharmaceuticals Company Information
  9. 8.2.2 Sun Pharmaceuticals Business Overview
  10. 8.2.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceuticals Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Malignant Mesothelioma Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Malignant Mesothelioma Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Malignant Mesothelioma Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Malignant Mesothelioma Drugs Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Roche Malignant Mesothelioma Drugs Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Malignant Mesothelioma Drugs Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Malignant Mesothelioma Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Fresenius Kabi
  56. 8.10.1 Fresenius Kabi Company Information
  57. 8.10.2 Fresenius Kabi Business Overview
  58. 8.10.3 Fresenius Kabi Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio
  60. 8.10.5 Fresenius Kabi Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Malignant Mesothelioma Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Polaris Pharmaceuticals
  68. 8.12.1 Polaris Pharmaceuticals Company Information
  69. 8.12.2 Polaris Pharmaceuticals Business Overview
  70. 8.12.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  72. 8.12.5 Polaris Pharmaceuticals Recent Developments
  73. 8.13 Ono Pharmaceutical
  74. 8.13.1 Ono Pharmaceutical Company Information
  75. 8.13.2 Ono Pharmaceutical Business Overview
  76. 8.13.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  78. 8.13.5 Ono Pharmaceutical Recent Developments
  79. 8.14 Nichi-Iko Pharmaceutical
  80. 8.14.1 Nichi-Iko Pharmaceutical Company Information
  81. 8.14.2 Nichi-Iko Pharmaceutical Business Overview
  82. 8.14.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  84. 8.14.5 Nichi-Iko Pharmaceutical Recent Developments
  85. 8.15 MolMed
  86. 8.15.1 MolMed Company Information
  87. 8.15.2 MolMed Business Overview
  88. 8.15.3 MolMed Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 MolMed Malignant Mesothelioma Drugs Product Portfolio
  90. 8.15.5 MolMed Recent Developments
  91. 8.16 Kyowa Hakko Kirin
  92. 8.16.1 Kyowa Hakko Kirin Company Information
  93. 8.16.2 Kyowa Hakko Kirin Business Overview
  94. 8.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio
  96. 8.16.5 Kyowa Hakko Kirin Recent Developments
  97. 8.17 Corden Pharma
  98. 8.17.1 Corden Pharma Company Information
  99. 8.17.2 Corden Pharma Business Overview
  100. 8.17.3 Corden Pharma Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Corden Pharma Malignant Mesothelioma Drugs Product Portfolio
  102. 8.17.5 Corden Pharma Recent Developments
  103. 8.18 Concordia International
  104. 8.18.1 Concordia International Company Information
  105. 8.18.2 Concordia International Business Overview
  106. 8.18.3 Concordia International Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Concordia International Malignant Mesothelioma Drugs Product Portfolio
  108. 8.18.5 Concordia International Recent Developments
  109. 8.19 Bristol-Myers Squibb
  110. 8.19.1 Bristol-Myers Squibb Company Information
  111. 8.19.2 Bristol-Myers Squibb Business Overview
  112. 8.19.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio
  114. 8.19.5 Bristol-Myers Squibb Recent Developments
  115. 8.20 Boehringer Ingelheim GmbH
  116. 8.20.1 Boehringer Ingelheim GmbH Company Information
  117. 8.20.2 Boehringer Ingelheim GmbH Business Overview
  118. 8.20.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio
  120. 8.20.5 Boehringer Ingelheim GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Malignant Mesothelioma Drugs Value Chain Analysis
  2. 9.1.1 Malignant Mesothelioma Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Malignant Mesothelioma Drugs Sales Mode & Process
  6. 9.2 Malignant Mesothelioma Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Malignant Mesothelioma Drugs Distributors
  9. 9.2.3 Malignant Mesothelioma Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst